Adamas to Present at Upcoming ICR Conference
Adamas Pharmaceuticals (Nasdaq: ADMS) announced that CEO Neil F. McFarlane will participate in a fireside chat during the ICR Conference 2021, scheduled for January 11-14, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Adamas Pharmaceuticals (Nasdaq: ADMS) announced that CEO Neil F. McFarlane will participate in a fireside chat during the ICR Conference 2021, scheduled for January 11-14, 2021. The chat will be broadcast live on January 14 at 11:30 a.m. Eastern Time via the company’s investor relations website. A replay will be accessible for 30 days post-event. Adamas is committed to developing innovative therapies that address neurological diseases, enhancing the quality of life for patients and caregivers.
Details
News Market Reaction – ADMS
The recorded move for ADMS in the trading session of this news was -2.71%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, will participate in a fireside chat at the ICR Conference 2021, being held January 11-14, 2021.
The fireside chat will be webcast live on January 14, 2021 at 11:30 a.m. Eastern Time on the investor relations section of the Adamas website at http://ir.adamaspharma.com/events-presentations. The replay will be available for 30 days.
About Adamas Pharmaceuticals, Inc.
At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.
Contact
| Media: Sarah Mathieson Vice President, Corporate Communications 510-450-3528 smathieson@adamaspharma.com |
| Investors: Peter Vozzo Managing Director Westwicke/ICR 443-213-0505 peter.vozzo@westwicke.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.